TAGS: Sealants
Polyganics has received 1.2 million EUR in funding from the European Fund for Regional Development (EFRO) through the Northern Netherlands Alliance (SNN) and the city and province of Groningen, to support clinical validation of Liver and Pancreas Sealant Patch. The grant will support safety and performance study in multiple renowned clinical centers across Europe.
Sealant Patch Adheres to Tissue During Healing Period
Polyganics’ easy-to-use device is made of the synthetic and safe bioresorbable polymers and optimized to effectively adhere and seal-off the surgically treated tissue throughout the critical healing period after hepato-pancreato-biliary (HPB) surgery. The sealant patch functions both as a sealant, withstanding the impact of aggressive bile and pancreatic fluids, and as a hemostat, controlling mild-to-moderate bleeding.
The sealant patch developed in close association with the surgical department of the University Medical Center Hamburg-Eppendorf (UKE), Germany, and with MercachemSyncom, a contract research organization located in Groningen.
New Liver and Pancreas Sealant Patch Integral to Polyganics’ Business Growth
EFRO aims to strengthen the regional economy by supporting local businesses to improve their competitive position, economic growth, and sustainable development, as well as by increasing employment opportunities. The innovative Liver and Pancreas Sealant Patch is integral to the Polyganics’s growth strategy. The sealant patch will pave the way for additional future applications in the field, increasing the strength and breadth of the company’s offering.
“
We are grateful to the EU, SNN and city and province of Groningen for their support towards progressing our Liver and Pancreas Sealant Patch into the next phase of development, particularly in the current unprecedented climate resulting from COVID-19. The grant is testament both to the quality of the preclinical data for this product, and to Polyganics’ strong growth outlook. As demand for products throughout our existing commercial portfolio continues to increase, we are pleased to be expanding into the challenging area of General Surgery, as we strive to provide unique bioresorbable medical devices to address unmet clinical needs,” said Rudy Mareel, chief executive offier of Polyganics.
Source: Polyganics